Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results [Yahoo! Finance]
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Yahoo! Finance
developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023. 2023 Corporate Highlights Closed IPO in January 2023 for net proceeds of $14.1 million Reached agreement in March 2023 with Dr. Reddy's Laboratories, Ltd. (Dr. Reddy's) to in-license an Abatacept (CTLA4-Ig) biosimilar candidate for the development of COYA 302 Presented positive results in March 2023 from a proof-of-concept academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) demonstrating that patients administered a combination of low dose interleukin-2 (LD IL-2) and CTLA4-Ig exhibited no progression on the ALSFRS-R Rating Scale at 24 weeks and showed minimal decline at 48 weeks. COYA 302 is Coya's combination of its proprietary LD IL-2 formulation with the immunomodulatory drug CTLA4-Ig. Presented positive results in May 2023 from an open-label, proof-of-concept academic cli
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases [Seeking Alpha]Seeking Alpha
- Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.MarketBeat
- Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumBusiness Wire
- Coya Therapeutics to Participate in the Mizuho Neuroscience SummitBusiness Wire
COYA
Sec Filings
- 3/29/24 - Form DEFA14A
- 3/28/24 - Form ARS
- 3/28/24 - Form DEFA14A
- COYA's page on the SEC website